Laser‐Activatable In Situ Vaccine Enhances Cancer‐Immunity Cycle

Author:

Wang Zhenyu123,You Tingting14,Su Qianyi1,Deng Wenjia1,Li JiaBao5,Hu Saixiang1,Shi Shengjun3,Zou Zhaowei1,Xiao Jisheng12,Duan Xiaopin1ORCID

Affiliation:

1. Department of General Surgery, Zhujiang Hospital Cancer Research Institute, School of Basic Medical Sciences Southern Medical University Guangzhou 510515 China

2. Department of Cardiology, Heart Center Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease Translational Medicine Research Center Zhujiang Hospital Southern Medical University Guangzhou 510280 China

3. Department of Burns and Wound Repairing, Zhujiang Hospital Southern Medical University Guangzhou 510280 China

4. Department of Blood Transfusion, The Fifth Affiliated Hospital Sun Yat‐sen University Zhuhai 519000 China

5. School of Pharmaceutical Sciences Southern Medical University Guangzhou 510515 China

Abstract

AbstractThe immune response in cancer reflects a series of carefully regulated events; however, current tumor immunotherapies typically address a single key aspect to enhance anti‐tumor immunity. In the present study, a nanoplatform (Fe3O4@IR820@CpG)‐based immunotherapy strategy that targets the multiple key steps in cancer‐immunity cycle is developed: 1) promotes the release of tumor‐derived proteins (TDPs), including tumor‐associated antigens and pro‐immunostimulatory factors), in addition to the direct killing effect, by photothermal (PTT) and photodynamic therapy (PDT); 2) captures the released TDPs and delivers them, together with CpG (a Toll‐like receptor 9 agonist) to antigen‐presenting cells (APCs) to promote antigen presentation and T cell activation; 3) enhances the tumor‐killing ability of T cells by combining with anti‐programmed death ligand 1 antibody (α‐PD‐L1), which collectively advances the outstanding of the anti‐tumor effects on colorectal, liver and breast cancers. The broad‐spectrum anti‐tumor activity of Fe3O4@IR820@CpG with α‐PD‐L1 demonstrates that optimally manipulating anti‐cancer immunity not singly but as a group provides promising clinical strategies.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Guangzhou Municipal Science and Technology Project

Publisher

Wiley

Subject

Mechanical Engineering,Mechanics of Materials,General Materials Science

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3